Allergy Therapeutics plc

Equities

AGY

GB00B02LCQ05

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:23 2024-05-01 am EDT			5-day change	1st Jan Change
2.875 ^GBX	-0.86%		+2.68%	+15.00%

Apr. 03	Allergy Therapeutics Announces Resignation of Mary Tavener as Non-Executive Director	CI
Mar. 27	EARNINGS AND TRADING: Solid State ups outlook; Quartix trading in line	AN

Allergy Therapeutics plc Provides Sales Guidance for the Second Half and Full Year Ending on 30 June 2024

March 27, 2024 at 03:00 am EDT

Allergy Therapeutics plc provided sales guidance for the second half and full year ending on 30 June 2024. For the second half of the financial year, sales are expected to be slightly higher than the previous year.

For the full year ending on 30 June 2024, sales are expected to be slightly lower than the corresponding period ending 30 June 2023.

Latest news about Allergy Therapeutics plc

Allergy Therapeutics Announces Resignation of Mary Tavener as Non-Executive Director	Apr. 03	CI
EARNINGS AND TRADING: Solid State ups outlook; Quartix trading in line	Mar. 27	AN
Allergy Therapeutics Gets OK to Draw Down GBP15 Million From Amended Loan Facility	Mar. 27	MT
AIM WINNERS & LOSERS: Norman Broadbent profit swing on rising revenue	Mar. 27	AN
Earnings Flash (AGY.L) ALLERGY THERAPEUTICS Reports Fiscal H1 Revenue GBP33.6M	Mar. 27	MT
Earnings Flash (AGY.L) ALLERGY THERAPEUTICS Posts Fiscal H1 Loss GBX-0.58	Mar. 27	MT
Allergy Therapeutics plc Provides Sales Guidance for the Second Half and Full Year Ending on 30 June 2024	Mar. 27	CI
Allergy Therapeutics plc Reports Earnings Results for the Half Year Ended December 31, 2023	Mar. 27	CI
Allergy Therapeutics starts dosing patients in peanut allergy trial	Mar. 12	AN
Allergy Therapeutics Announces Commencement of Subcutaneous Dosing of Peanut Allergic Patients in the Phase I/IIa PROTECT Trial Evaluating its Novel Virus-Like Particle Based Peanut Allergy Vaccine Candidate	Mar. 12	CI
Allergy Therapeutics plc Announces Appointment of Shaun Furlong to Board of Directors	Mar. 11	CI
Allergy Therapeutics forecasts revenue drop but trials going well	Feb. 14	AN
Alliance Pharma appoints chair; FireAngel sales down	Feb. 05	AN
Scancell's Chief Development Officer to Step Down	Feb. 05	MT
Allergy Therapeutics resumes trading on AIM; annual revenue plunges	Jan. 30	AN
Allergy Therapeutics amends facility, plans warrant issue	Dec. 27	AN
Allergy Therapeutics Agrees Amendment to Loan Facility	Dec. 27	MT
EARNINGS AND TRADING: Redx full year revenue tumbles; loss widens	Dec. 15	AN
Allergy Therapeutics' Allergic Rhinoconjunctivitis Treatment Returns Positive Data in Late-stage Trial	Dec. 13	MT
Allergy Therapeutics shares jump as hails grass allergy jab data	Dec. 13	AN
AIM WINNERS & LOSERS: Impellam climbs on GBP483 million takeover offer	Dec. 13	AN
Allergy Therapeutics plc Provides an Update on the Data Analysis of Its Pivotal G306 Phase III Trial of Grass MATA MPL	Dec. 13	CI
Allergy Therapeutics in Advanced Talks for Potential Funding; Shares Drop	Dec. 11	MT
AIM WINNERS & LOSERS: Synectics to beat forecast; Dekel shares jump	Dec. 11	AN
Allergy Therapeutics stock falls on lower sales outlook	Dec. 11	AN

Chart Allergy Therapeutics plc

Duration

Period

More charts

Company Profile

Allergy Therapeutics plc is a United Kingdom-based integrated specialty pharmaceutical company. The Company is focused on the treatment and diagnosis of allergic disorders, including aluminum-free immunotherapy vaccines that have the potential to cure disease. The Company sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional ten countries. Its pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA, Bee Venom SCIT, Wasp Venom SCIT, Ragweed MATA MPL, Trees MATA, Trees MATA MPL, Peanut SCIT and others. Its commercial portfolio of products includes Pollinex, Venomil and Acarovac. It operates in Austria, Germany, Italy, the Netherlands, Spain, Switzerland, and the United Kingdom.

Sector

Biotechnology & Medical Research

Calendar

2024-09-24 - Q4 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
ALLERGY THERAPEUTICS PLC	+15.00%	173M
VERTEX PHARMACEUTICALS INCORPORATED	-1.17%	102B
REGENERON PHARMACEUTICALS, INC.	+2.87%	96.09B
ARGENX SE	+2.13%	22.28B
BIONTECH SE	-14.77%	21.4B
GENMAB A/S	-8.79%	18.14B
WUXI APPTEC CO., LTD.	-39.98%	17.02B
BEIGENE, LTD.	-13.21%	16.09B
NEUROCRINE BIOSCIENCES, INC.	+8.55%	13.83B
SAREPTA THERAPEUTICS, INC.	+35.75%	11.97B

Bio Therapeutic Drugs